British Journal of Clinical Pharmacology 2006: Vol 61 Index & Table of Contents

2006·4.8 MB·English

British Journal of Clinical Pharmacology
AUTHOR INDEX
AARONS, L. see SIMPSON, J.A. BEGG, E.J. see ARONSON, J.K. Interpatient variability in the
ABBOTT, R. see SIDHU, J. BEGG, E.J. see GARDINER, S.J. pharmacokinetics of the HIV
ACUNA, M., EATON, L., CIFUENTES, L. BEGGS, S. see TITCHEN, T. non-nucleoside reverse transcriptase
& MASSARDO, D. Genetic variants in BENKO, R. see MATUZ, M. inhibitor efavirenz: the effect of
the enhancer region of the thymidylate BERGSTRAND, L.C. see MAGNUSSON, M. gender, race, and CYP2B6
synthase gene in the Chilean population: BERNSDORF, A., GIESSMANN, T., polymorphism: 148
778 MODESS, C., WEGNER, D., BURKEY, J.L. see YEO, K.P.
TIO, M.-L. N-acetylcysteine — passe- IGELBRINK, S., HECKER, U., BYRNE, C. see STAATZ, C.E.
partout or much ado about nothing?: 5 HAENISCH, S., CASCORBI, L.,
AM, C.A.S. see CHIK, Z. TERHAAG, B. & SIEGMUND, W. “AIXAS, U. see PEREIRA, S.A.
.AM, C.A.S. Pharmacokinetics of a new Simvastatin does not influence the “ALCINO, L.J. see BOYD, I.W.
testosterone transdermal delivery system, intestinal P-glycoprotein and MPR2, and *>ALLAHAN, M.M. see SIMOES, J.A.
TDS*-testosterone in healthy males: the disposition of talinolol after chronic “AMARGO, R.P.S. see SIMOES, J.A
275ALFARO, R.M. see ROBERTSON, medication in healthy subjects genotyped “APRON, L. see WYPLOSZ, B.
S.M. for the ABCB1, ABCC2 and SLCO1B1 *ARDAROPOLI, S. see TODROS, T.
LAIN, T.J. see DHESI, J.K. polymorphisms: 440 “ARDOT, J.M. see CHASSAING, C.
-LEGAERT, K., ANDERSON, B.J., BERTELE, V. see JOPPI, R. RRAR “AAA ARDVAADJAALD- GONZALEZ, S. see
COSSEY, V. & HOLFORD, N.H.G. BERTRAND, X. see MULLER, A. QUELLET, D.
Limited predictability of amikacin BEYER, J. & SCHELLONG, S. Bilateral “ASCORBI, I. see BERNSDORF, A.
clearance in extreme premature neonates plantar tendinitis during levofloxacin CASTEL, J.-M., FIGUERAS, A. & VIGO,
at birth: 39 therapy: 609 J.-M. The internet as a tool in clinical
ALVES, V.M.N. see SIMOES, J.A. BIAGINI, G.A. see EDWARDS, G. pharmacology: 787
ANDERSON, B.J. see ALLEGAERT, K. BIDSTRUP, T.B., DAMKIER, P., OLSEN, CELASCO, G. see BRUNNER, M.
ANTIKAINEN, M. see HEDMAN, M. A.K., EKBLOM, M., KARLSSON, A. & CHASSAING, C., SCHMIDT, J.,
ARONSON, J.K. A prescription for better BROSEN, K. The impact of CYP2C8 ESCHALIER, A., CARDOT, J.M. &
prescribing: 487 polymorphism and grapefruit juice on the DUBRAY, C. Hyperalgesia induced by
ARONSON, J.K. Clinical Pharmacology: pharmacokinetics of repaglinide: 49 cutaneous freeze injury for testing
Past, Present, and Future: 647 BIERMASZ, N.R. see PEREIRA, A.M. analgesics in healthy volunteers: 389
ARONSON, J.K. Medicines and the media: BIES, R.R. see FENG, Y. CHEW, S.L. see CHIK, Z.
121 BINH. V.Q. see CUONG, B.T. CHIK, Z., JOHNSTON, A., TUCKER, A.T.,
ARONSON, J.K. Monitoring for harms of BJORKMAN, S. see MAGNUSSON, M. CHEW, S.L., MICHAELS, L. &
therapy: 365 BLAKEY, J. see CLAYTON, J.A. ‘CHRIS’ DELANEY, J.A., OPATRNY, L.
ARONSON, J.K. Rare diseases and orphan BLOM, A.T.G. see HUGTENBURG, J.G. & SUISSA, S. Warfarin use and the risk
drugs: 243 BOJANG, K. see SIMPSON, J.A. of motor vehicle crash in older drivers:
ARONSON, J.K., LENNARD, MLS., BOYD, I.W., MCEWEN, J. & CALCINO, 229
RITTER, J.M., BABER, N.S., BEGG, L.J. A study of codispensing with sodium CHINITZ, D.P. see KAHAN, N.R.
E.J. & LEWIS, L.D. Today’s science, alendronate in Australia: 470 CHOW, M.S.S. see TOMLINSON, B.
tomorrow's medicines: | BOZZELLA, R. see BRUNNER, M. CIFUENTES, L. see ACUNA, M.
ARONSON, J.K., LENNARD, M.S., BROSEN, K. see BIDSTRUP, T.B. CLARK, D.W.J. see HARRISON-
RITTER, J.M., BABER, N.S., BEGG, BRADSHAW, C.M. see HOU, R.H. WOOLRYCH, M.
E.J. & LEWIS, L.D. Editors’ Report BRAMSON, C. see OUELLET, D. CLAYTON, J.A., RODGERS, S., BLAKEY,
2005: 492 BRANCO, T. see PEREIRA, S.A. J., AVERY, A. & HALL, I.P. Thiazide
ASCHER, J. see SIDHU, J BRUNNER, M., ZIEGLER, S., DI diuretic prescription and electrolyte
AUDIKOVSZKY, M. see PARAGH, G. STEFANO, A.F.D., DEHGHANYAR, P., abnormalities in primary care: 87
AVERY, A. see CLAYTON, J.A. KLETTER, K., TSCHURLOVITS, M.., CORTE-REAL, R.M. see PEREIRA, S.A.
VILLA, R., BOZZELLA, R.., COLEMAN, J.J., FERNER, R.E. & EVANS,
BABER, N.S. see ARONSON, J.K. CELASCO, G., MORO, L., RUSCA, A., S.J.W. Monitoring for adverse drug
BACKMAN, J.T. see JAAKKOLA, T. DUDCZAK, R. & MULLER, M. reactions: 371
BAHAMONDES, L.G. see SIMOES, Gastrointestinal transit, release and COLLER, J.K. see DAVIES, B.J.
J.A. plasma pharmacokinetics of a new oral COMINACINI, L. see MINUZ, P.
BAILEY, D.G. see TIRONA, R.G. budesonide formulation: 31 COMPAGNON, P. see JOANNIDES, R.
BARROW, P., WALLER, P. & WISE, L. DINSKY, A. see RESCH, U. COSSEY, V. see ALLEGAERT, K.
Comparison of hospital episodes with LLMAN, J. see SIDHU, J. CRANSWICK, N. see TITCHEN, T.
‘drug-induced’ disorders and JRGER, D., VAN DER HEIDEN, I., LA CUONG, B.T., BINH, V.Q., DUY,
spontaneously reported adverse drug PORTE, C., VAN DER ENDE, M., B.D.D.N., LOVELL, C.M.,
reactions: 233 GROENEVELD, P., RICHTER, C., RIECKMANN, K.H. & EDSTEIN, M.D.
BEARD, K. see WALLER, P.C. KOOPMANS, P., KROON, F., Does gender, food or grapefruit juice
BECK, C.R. see REHILL, N. SPRENGER, H., LINDEMANS, J., alter the pharmacokinetics of primaquine
BEDDING, A.W. see FORGUE, S.T. SCHENK, P. & VAN SCHAIK, R. in healthy subjects?: 682
© 2006 Blackwell Publishing Ltd Br J Clin Pharmacol | 61:6 | 791-796 791
Author Index
DAIMON, T. see YAMADA, H FAIFERMAN, I. see SINGH, D. HAJDU, E. see MATUZ, M.
DALLOW, N. see SINGH, D FALLOON, J. see ROBERTSON, S.M. HALL, I.P. see CLAYTON, J.A.
DAMKIER, P. see BIDSTRUP, T.B. FAVA, C. see MINUZ, P. HARANGI, M. see PARAGH, G.
DAVIES, B.J., COLLER, J.K., JAMES, FENG, Y., POLLOCK, B.G., FERRELL, HARRISON-WOOLRYCH, M., CLARK,
H.M., SOMOGYI, A.A., HOROWITZ, R.E., KIMAK, M.A., REYNOLDS III, D.W.J., HILL, G.R., REES, M.I. &
J.D. & SALLUSTIO, B.C. The influence C.F. & BIES, R.R. Paroxetine: SKINNER, J.R. QT interval prolongation
of CYP2D6 genotype on trough plasma population pharmacokinetic analysis in associated with sibutramine treatment:
perhexiline and cis-OH-perhexiline late-life depression using sparse 464
concentrations following a standard concentration sampling: 558 HAUBEN, M. & REICH, L. Response to
loading regimen in patients with FERNER, R.E. see COLEMAN, J.J. letter by Levine et al: 115
myocardial ischaemia: 321 FERRELL, R.E. see FENG, Y. HAWKEY, C.J., HAWKEY, G.M..,
DE BOER, A. see MANTEL-TEEUWISSE, FERRO, A. see SAHA, M. EVERITT, S., SKELLY, M.M., STACK,
A.K FIGUERAS, A. see CASTEL, J.-M. W.A. & GRAY, D. Increased risk of
DE BRUIJN, M. see HESSE, C FITZGERALD, C. see KIM, J. myocardial infarction as first
DE HAAN, M. see VOLLEBREGT, J.A FITZGERALD, D. see QUINN, M. manifestation of ischaemic heart disease
DE VRIES, M. see HESSE, C. FORGUE, S.T., PATTERSON, B.E., and nonselective nonsteroidal anti-
DE VRIES, T.P.G.M. see VOLLEBREGT, BEDDING, A.W., PAYNE, C.D., inflammatory drugs: 730
JLA PHILLIPS, D.L., WRISHKO, R.E. & HAWKEY, G.M. see HAWKEY, C.J.
DEBRECZENI, L. see PARAGH, G MITCHELL, M.I. Tadalafil HENON, T. see MULLER, A.
DEHGHANYAR, P. see BRUNNER, M. pharmacokinetics in healthy subjects: 280 HECKER, U. see BERNSDORF, A.
DHESI, J.K., ALLAIN, T.J., MANGONI, FORMENTINI, E. see ROBERTSON, S.M. HEDMAN, M., ANTIKAINEN, M.,
A.A. & JACKSON, S.H.D. The FOSTER, D.J.R. see MORRISH, G.A HOLMBERG, C., NEUVONEN, M..,
implications of a growing evidence base FRANCIS, E. see SIDHU, J EICHELBAUM, M., KIVISTO, K.T.,
for drug use in elderly patients. Part 4 FREEMAN, C. see HOU, R.H. NEUVONEN, PJ. & NIEMI, M.
Vitamin D and bisphosphonates fot FRIBERG, L.E., ISBISTER, G.K. & Pharmacokinetics and response to
fractures and osteoporosis: 521 DUFFULL, S.B pravastatin in paediatric patients with
DI STEFANO, A.F.D. see BRUNNER, M Pharmacokinetic-pharmacodynamic familial hypercholesterolaemia and in
DIELEMAN, J.P. see ZIERE, G. modelling of QT interval prolongation paediatric cardiac transplant
DINGEMANSE, J., GUNAWARDENA, following citalopram overdoses: 177 recipients in relation to polymorphisms
K.A. & VAN GIERSBERGEN, P.L.M. 'RUTA. T., SHIRAI, N., SUGIMOTO, of the SLCO/B/ and ABCB/ genes: 706
Comparison of the pharmacokinetics, M., NAKAMURA, A. & HISHIDA, A. HEIL, A. see MAGNUSSON, M.
pharmacodynamics and tolerability of Hydroxylation of lansoprazole in poor HENDERSON, A. see SINGH, D.
tezosentan between Caucasian and metabolizers of CYP2C19: 361 HESSE, C., LUNTZ, S.P., SIEDLER, H.,
Japanese subjects: 405 UNNEBRINK, K., MIKUS, G., DE
DOLLERY, C.T. Clinical pharmacology GARATTINI, S. see JOPPI, R. BRUIJN, M., ZONDAG, E., DE VRIES,
the first 75 years and a view of the GARDINER, S.J., DOOGUE, M.P., M., SEIBERT-GRAFE, M. & HAEFELI,
future: 650 ZHANG, M. & BEGG, E.J. W.E. Kinetics and dynamics of the
DONNELLY, R., WANG, B. & QU, X Quantification of infant exposure to peripheral neurokinin-1 receptor
Type 2 diabetes in China: partnerships in celecoxib through breast milk: 101 antagonist SLV317 in healthy
education and research to evaluate new GARDNER, M.J. see OUELLET, D. individuals: 414
antidiabetic treatments: 702 GARNER, R.C. & LAPPIN, G. The phase 0 HILL, G.R. see HARRISON-WOOLRYCH,
DOOGUE, M.P. see GARDINER, S.J microdosing concept: 367 M
DORO, P. see MATUZ, M GERMANO, I. see PEREIRA, S.A HIRAOKA, H. see TAKIZAWA, E.
DUBRAY, C. see CHASSAING, C GIESSMANN, T. see BERNSDORF, A HISHIDA, A. see FURUTA, T.
DUDCZAK, R. see BRUNNER, M GILLAM, E.M.J. see POLASEK, T.M. HOGLUND, P. see MAGNUSSON, M.
DUFFULL, S.B. see FRIBERG, L.E. GOLDMAN, M. see SINGH, D. HO, W.F. see KOO, S.H.
DUY, B.D.D.N. see CUONG, B.T. GOOSEN, A. see SINGH, D. HOFMAN, A. see MANTEL-TEEUWISSE,
GOTO, F. see TAKIZAWA, E. A.K
EATON, L. see ACUNA, M. GRAY, D. see HAWKEY, C.J. HOFMAN, A. see ZIERE, G.
EDSTEIN, M.D. see CUONG, B.T. GRIMM, S.W., RICHTAND, N.M., HOLFORD, N.H.G. see ALLEGAERT, K.
EDWARDS, G. & BIAGINI, G.A. Resisting WINTER, H.R., STAMS, K.R. & HOLMBERG, C. see HEDMAN, M.
resistance: dealing with the irrepressible REELE, S.B. Effects of cytochrome HOROWITZ, J.D. see DAVIES, B.J.
problem of malaria: 690 P450 3A modulators ketoconazole and HOSSEINI, S.Y. see SAFARINEJAD, M.R.
EDWARDS, G. see SIMPSON, J.A. carbamazepine on quetiapine HOU, R.H., SCAIFE, J., FREEMAN, C.,
EICHELBAUM, M. see HEDMAN, M. pharmacokinetics: 58 LANGLEY, R.W., SZABADI, E. &
EKBLOM, M. see BIDSTRUP, T.B. GROENEVELD, P. see BURGER, D. BRADSHAW, C.M. Relationship
ELLIOT, D.J. see POLASEK, T.M GROVER, A. see SIDHU, S. between sedation and pupillary function:
ELLIOT, D.J. see UCHAIPICHAT, V GRUNAU, R.E. see KIM, J. comparison of diazepam and
ENCK, P. see OTTO, B. GUNAWARDENA, K.A. see diphenhydramine: 752
ERDEI, A. see PARAGH, G DINGEMANSE, J. HSU, E. Reflections on the ‘discovery’ of
ESCHALIER, A. see CHASSAING, C. GUNNELL, D. see MARTIN, R.M the antimalarial ginghao: 666
EVANS, S.J.W. see COLEMAN, J.J. HUGHES, D. see SIMPSON, J.A.
EVANS, S.J.W. see WALLER, P.C. HAEFELI, W.E. see HESSE, C. HUGTENBURG, J.G. see VOLLEBREGT,
EVERITT, S. see HAWKEY, C.J. HAENISCH, S. see BERNSDORF, A. J.A.
792 | 61:6 | BrJ Clin Pharmacol
Author Index |
HUGTENBURG, J.G., BLOM, A.T.G. & KLOSTERHALFEN, S. see OTTO, B. MANGONI, A.A. & JACKSON, S.H.D. The
KISOENSINGH, S.U. Initial phase of KLUNGEL, O.H. see MANTEL- implications of a growing evidence base
chronic medication use; patients’ reasons TEEUWISSE, A.K. for drug use in elderly patients. Part 2.
for discontinuation: 352 KNIGHTS, K.M., MANGONI, A.A. & ACE inhibitors and angiotensin receptor
MINERS, J.O. Non-selective blockers in heart failure and high
IACOB, M. see JOANNIDES, R. nonsteroidal anti-inflammatory drugs and cardiovascular risk patients: 502
IGELBRINK, S. see BERNSDORF, A. cardiovascular events: is aldosterone the MANGONTI, A.A. & JACKSON, S.H.D. The
ILLYES, L. see PARAGH, G. silent partner in crime?: 738 implications of a growing evidence base
ISBISTER, G.K. see FRIBERG, L.E. KOO, S.H., HO, W.F. & LEE, E.J.D. for drug use in elderly patients. Part 3.
ISHII, K. see TASHIRO, M. Genetic polymorphisms in KCNQI, f-adrenoceptor blockers in heart failure
ISHIWATA, K. see TASHIRO, M. HERG, KCNE1 and KCNE2 genes in and thrombolytics in acute myocardial
the Chinese, Malay and Indian infarction: 513
JAAKKOLA, T., BACKMAN, J.T., populations of Singapore: 301 MANGONI, A.A. see DHESI, J.K.
NEUVONEN, M., LAITILA, J. & KOOPMANS, P. see BURGER, D. MANGONI, A.A. see KNIGHTS, K.M.
NEUVONEN, P.J. Effect of rifampicin KOPPESCHAAR, H.P.F. see PEREIRA, MANTEL-TEEUWISSE, A.K., KLUNGEL,
on the pharmacokinetics of pioglitazone: A.M. O.H., HOFMAN, A., VERSCHUREN,
70 KOVACSAY, A. see PARAGH, G. W.M.M., TRIENEKENS, P.H.,
JACKSON, S.H.D. see DHESI, J.K KROON, F. see BURGER, D. PORSIUS, A.J., STRICKER, B.H.CH. &
JACKSON, S.H.D. see MANGONI, A.A. DE BOER, A. Prescribing behaviour
JAMES, H.M. see DAVIES, B.J. LA PORTE, C. see BURGER, D. according to Dutch and European
JOANNIDES, R., MOORE, N., [ACOB, M., LAITILA, J. see JAAKKOLA, T. guidelines on the management of
COMPAGNON, P., LEREBOURS, G., LAMPREIA, F. see PEREIRA, S.A. hypercholesterolaemia (1992-1999): 592
MENARD, J.-F. & THUILLEZ, C. LANGLEY, R.W. see HOU, R.H. MANYANDO, C. see SIMPSON, J.A.
Comparative effects of ivabradine, a LAPPIN, G. see GARNER, R.C. MARSHALL, K. see LEWINGTON, G.
selective heart rate-lowering agent, and LASENBY, S. see SINGH, D. MARTIN, R.M., MAY, M. & GUNNELL,D.
propranolol on systemic and cardiac LEE, E.J.D. see KOO, S.H. Did intense adverse media publicity
haemodynamics at rest and during LENNARD, M.S. see ARONSON, J.K. impact on prescribing of paroxetine and
exercise: 127 LEREBOURS, G. see JOANNIDES, R. the notification of suspected adverse drug
JOB, S. see SIDHU, J. LEVINE, J.G., TONNING, J.M. & reactions? Analysis of routine databases,
JOHNSTON, A. see CHIK, Z. SZARFMAN, A. Reply: The evaluation 2001-2004: 224
JOPPI, R., BERTELE, V. & GARATTINI, of data mining methods for the MASSARDO, D. see ACUNA, M.
S. Orphan drug development is simultaneous and systematic detection of MATUZ, M., BENKO, R., DORO, P.,
progressing too slowly: 355 safety signals in large databases: lessons HAJDU, E., NAGY, G., NAGY, E.,
to be learned: 105 MONNET, D.L. & SOOS, G. Regional
KAGAYA, H. see MIURA, M. LEWINGTON, G. & MARSHALL, K. variations in community consumption of
KAHAN, E. see KAHAN, N.R. Access to emergency hormonal antibiotics in Hungary, 1996-2003: 96
KAHAN, N.R., CHINITZ, D.P., contraception from community MAUCK, C.K. see SIMOES, J.A.
WAITMAN, D.-A. & KAHAN, E. pharmacies and family planning clinics: MAY, M. see MARTIN, R.M.
When gatekeepers meet the sentinel: the 605 MCEWEN, J. see BOYD, I.W.
impact of a prior authorization LEWIS, B.C. see POLASEK, T.M. MECHOULAM, R. Cannabinoids as
requirement for cefuroxime on the LEWIS, L.D. see ARONSON, J.K. Therapeutics: 242
prescribing behaviour of community- LILLO-LE LOUET, A. see WYPLOSZ, B. MENARD, J.-F. see JOANNIDES, R.
based physicians: 341 LIM, M.T. see YEO, K.P. METZ, J.C.M. see VOLLEBREGT, J.A.
KAMALI, F. & PIRMOHAMED, M. The LINDEMANS, J. see BURGER, D. MICHAELS, L. see CHIK, Z.
future prospects of pharmacogenetics in LOVELL, C.M. see CUONG, B.T. MIKUS, G. see HESSE, C.
oral anticoagulation therapy: 746 LOWE, S.L. see YEO, K.P. MINERS, J.O. see KNIGHTS, K.M.
KANABAR, D. Adverse drug reactions to LUNTZ, S.P. see HESSE, C. MINERS, J.O. see POLASEK, T.M.
NSAIDs: 240 MINERS, J.O. see UCHAIPICHAT, V.
KANEKO, S. see YASUI-FURUKORI, N. MACKENZIE, P.I. see UCHAIPICHAT, V. MINUZ, P., FAVA, C. & COMINACINI, L.
KARLSSON, A. see BIDSTRUP, T.B. MAGNUSSON, M., BERGSTRAND, LC., Oxidative stress, antioxidants, and
KENT, N. see KIM, J. BJORKMAN, S., HEIJL, A., ROTH, B. vascular damage: 774
KIM, J., RIGGS, K.W., MISRI, S., KENT, & HOGLUND, P. A placebo-controlled MISRI, S. see KIM, J.
N., OBERLANDER, T.F.. GRUNAU, study of retinal blood flow changes by MITCHELL, M.I. see FORGUE, S.T.
R.E., FITZGERALD, C. & RURAK, pentoxifylline and metabolites in MIURA, M., KAGAYA, H., TADA, H.,
D.W. Stereoselective disposition of humans: 138 UNO, T., YASUI-FURUKORI, N..,
fluoxetine and norfluoxetine during MAHMOOD, I. Prediction of drug clearance TATEISHI, T. & SUZUKI, T.
pregnancy and breast-feeding: 155 in children from adults: a comparison of Enantioselective disposition of
KIMAK, M.A. see FENG, Y. several allometric methods: 545 rabeprazole in relation to CYP2C19
KIMURA, Y. see TASHIRO, M. MALHOTRA, S. see SIDHU, S. genotypes: 315
KISOENSINGH, S.U. see HUGTENBURG, MANGONI, A.A. & JACKSON, S.H.D. The MOCHIZUKI, H. see TASHIRO, M.
J.G. implications of a growing evidence base MODESS, C. see BERNSDORF, A.
KIVISTO, K.T. see HEDMAN, M. for drug use in elderly patients. Part 1. MONNET, D.L. see MATUZ, M.
KLETTER, K. see BRUNNER, M. Statins for primary and secondary MONNET, D.L. see MULLER, A.
KLOSE, J. see OTTO, B. cardiovascular prevention: 494 MONTEIRO, E.C. see PEREIRA, S.A.
Br J Clin Pharmacol | 61:6 | 793
MOORE, N. see JOANNIDES, R ERDEI, A., AUDIKOVSZKY, M.., oxidative stress and modulation of
MORO, L. see BRUNNER, M DEBRECZENI, L., KOVACSAY, A. autoantibodies against modified low-
MORRISH, G.A., FOSTER, D.J.R. & ILLYES, L. & PADOS, G. Ciprofibrate density lipoprotein after rosuvastatin
SOMOGYI, A.A. Differential in vitro increases paraoxonase activity in patients therapy: 262
inhibition of M3G and M6G formation with metabolic syndrome: 694 REYNOLDS II, C.F. see FENG, Y
from morphine by (R)- and (S) PATTERSON, B.E. see FORGUE, S.T. RICHIR, M.C. see VOLLEBREGT, J.A.
methadone and structurally related PAYNE, C.D. see FORGUE, S.T. RICHTAND, N.M. see GRIMM, S.W.
opioids: 326 PENZAK, S.R. see ROBERTSON, S.M. RICHTER, C. see BURGER, D.
MOTOMURA, S. see UNO, T PEREIRA, A.M., VAN DER KLAAUW, RIECKMANN, K.H. see CUONG, B.T.
MULLER, M. see BRUNNER, M \.A., KOPPESCHAAR, H.P.F., SMIT, RIEPL, R.L. see OTTO, B.
MULLER, A., MONNET, DI , TALON, D., J.W.A., VAN THIEL, S.W., VAN RIGGS, K.W. see KIM, J.
HENON, T. & BERTRAND, X DOORN, J., BIERMASZ, N.R., RITTER, J. & WARREN, J. ASCOT -— old
Discrepancies between prescribed daily ROELFSEMA, F. & ROMIJN, J.A. or new drugs for blood pressure?: 363
doses and WHO defined daily doses of Efficacy of needle-free administration of RITTER, J.M. see ARONSON, J.K.
antibacterials at a university hospital recombinant human growth hormone in ROBERTSON, S.M., FORMENTINI, E.,
SR5 adults with growth hormone deficiency: ALFARO, R.M., NATARAJAN, V.,
MURAKAMI, H. see MURAKAMI, ¥ 45| FALLOON, J. & PENZAK, S.R. Lack of
MURAKAMI, Y., TANAKA, T., PEREIRA, S.A., BRANCO, T., CORTE sex-related differences in saquinavir
MURAKAMI, H., TSUJIMOTO, M.., REAL, R.M., GERMANO, L., pharmacokinetics in an HIV-seronegative
OHTANI, H. & SAWADA, ¥ LAMPREIA, F., CAIXAS, U. & cohort: 379
Pharmacokinetic modelling of the MONTEIRO, E.C. Long-term and RODGERS, S. see CLAYTON, J.A.
interaction between St John’s wort and concentration-dependent beneficial effect RODVALD, K.A. see PISCITELLI, S.C.
ciclosporin A: 671 of efavirenz on HDL-cholesterol in HIV- ROELFSEMA, F. see PEREIRA, A.M.
infected patients: 601 ROMAN, D. see OUELLET, D.
NAGY,E . see MATUZ, M PERUCCA, E. Clinically relevant drug ROMIJN, J.A. see PEREIRA, A.M.
NAGY, G. see MATUZ, M interactions with antiepileptic drugs: ROTH, B. see MAGNUSSON, M.
NAKAMURA, A. see FURUTA,1 PHILIPSON, R. see SIDHU, J RURAK, D.W. see KIM, J.
NAKASHIMA, M. see YAMADA, H PHILLIPS, D.L. see FORGUE, S.T. RUSCA, A. see BRUNNER, M.
NATARAJAN,V . see ROBERTSONS,.M PIRMOHAMED, M. see KAMALI, F
NEUVONEN, M. see HEDMAN,M PISCITELLI, S.C. & RODVALD, K.A SAFARINEJAD, M.R. & HOSSEINI, S-Y.
NEUVONEN, M. see JAAKKOLA, T Drug Interactions in Infectious Diseases, Safety and efficacy of tramadol in the
NEUVONEN, P.J. see HEDMAN, M. 2nd edn: 611 treatment of idiopathic detrusci
NEUVONEN, P.J. see JAAKKOLA, 7 POLASEK, T.M., ELLIOT, D.J., overactivity: a double-blind, placebo
NIEMI, M. see HEDMAN, M SOMOGYI, A.A., GILLAM, E.M.J., controlled, randomized study: 456
LEWIS, B.C. & MINERS, J.O. An SAHA, M. & FERRO, A. Cardiac stem cell
O*’SHAUGHNESSY, K.M. HapMap evaluation of potential mechanism-based therapy: present and future: 797
pharmacogenomics, and the goal of inactivation of human drug metabolizing SAITO, S. see TAKIZAWA, E
personalized prescribing: 783 cytochromes P450 by monoamine SAKURADA, Y. see TASHIRO, M.
OBERLANDER, T-F. see KIM, J oxidase inhibitors, including isoniazid SALLUSTIO, B.C. see DAVIES, B.J.
ODA, K. see TASHIRO, M 570 SASAKI, T. see TASHIRO, M
OGGE, G. see TODROS, T POLLOCK, B.G. see FENG, Y SAWADA, Y. see MURAKAMI, Y.
OHKUBO, T. see UNO, 1 POLS, H.A.P. see ZIERE, G. SCAIFE, J. see HOU, R.H
OHTANI, H. see MURAKAMI, Y PORSIUS, A.J. see MANTEL-TEEUWISSE, SCHELLONG, S. see BEYER, J.
OLSEN, A.K. see BIDSTRUP, T.B A.K SCHENK, P. see BURGER, D
OPATRNY, L. see “*CHRIS’ DELANEY, J.A SCHMIDT, J. see CHASSAING, C
OTTO, B., RIEPL, R.L., OTTO, C., QU, X. see DONNELLY, R. SCHWARTZ, J. see SIMOES, J.A
KLOSE, J., ENCK, P. & QUINN, M. & FITZGERALD, D. Platelet SEIBERT-GRAFE, M. see HESSE, C.
KLOSTERHALFEN, S. u-Opiate function: assessment, diagnosis and SERES, I. see PARAGH, G
receptor agonists — a new treatment: 610 SESOKO, S. see YAMADA, H
pharmacological approach to prevent SHAFIQ, N. see SIDHU, S.
motion sickness?: 27 RAMAEKERS, J.G. see THEUNISSEN, SHIMIZU, M. see UNO, T.
OTTO, C. see OTTO, B E.l SHIMIZU, M., UNO, T., SUGAWARA, K.
OQUELLET, D., BRAMSONC,.. , RANDINITIS, E. see OUELLET, D & TATEISHI, T. Effects of itraconazole
CARVAJAL-GONZALEZ, S., ROMAN, REELE, S.B. see GRIMM, S.W and diltiazem on the pharmacokinetics of
D., RANDINITIS, E., REMMERS, A. & REES, M.1. see HARRISON-WOOLRYCH, fexofenadine, a substrate of P-
GARDNER, M.J. Effects of lasofoxifene M glycoprotein: 538
on the pharmacokinetics and REHILL, N., BECK, C.R., YEO, K.R. & SHIRAI, N. see FURUTA, T.
pharmacodynamics of single-dose YEO, W.W. The effect of chronic SIDHU, J., JOB, S.. BULLMAN, J.,
warfarin: 741 tobacco smoking on arterial stiffness: FRANCIS, E., ABBOTT, R., ASCHER,
767 J. & THEIS, J.G.W. Pharmacokinetics
PADOS,G . see PARAGH,G REICH, L. see HAUBEN, M and tolerability of lamotrigine and
PALADINI, D. see TODROS, 1 REMMERS, A. see OUELLET, D olanzapine coadministered to healthy
PANDHI, P. see SIDHU, S. RESCH, U., TATZBER, F., BUDINSKY, A. subjects: 420
PARAGH, G., SERES, I., HARANGI, M., & SINZINGER, H. Reduction of SIDHU, J., JOB, S., SINGH, S. &
61:6 Br J Clin Pharmacol
Author Index |
PHILIPSON, R. The pharmacokinetic SUGAWARA, K. see UNO, T. TRIENEKENS, P.H. see MANTEL-
and pharmacodynamic consequences of SUGIMOTO, M. see FURUTA, T. TEEUWISSE, A.K.
the co-administration of lamotrigine and SUISSA, S. see ‘CHRIS’ DELANEY, J.A. TSCHURLOVITS, M. see BRUNNER, M.
a combined oral contraceptive in healthy SUZUKI, T. see MIURA, M. TSUJIMOTO, M. see MURAKAMI, Y.
female subjects: 191 SZABADI, E. Drugs for sleep disorders: TUCKER, A.T. see CHIK, Z.
SIDHU, S., SHAFIQ, N., MALHOTRA, S., mechanisms and therapeutic prospects:
PANDHI, P. & GROVER, A. A meta- 761 UCHAIPICHAT, V., WINNER, L.K.,
analysis of trials comparing Cypher and SZABADI, E. see HOU, R.H. MACKENZIE, P.I., ELLIOT, D.J..
Taxus stents in patients with obstructive SZARFMAN, A. see LEVINE, J.G. WILLIAMS, J.A. & MINERS, J.O.
coronary artery disease: 720 Quantitative prediction of in vivo
SIEDLER, H. see HESSE, C. TADA, H. see MIURA, M. inhibitory interactions involving
SIEGMUND, W. see BERNSDORF, A. TAKIZAWA, D. see TAKIZAWA, E. glucuronidated drugs from in vitro data:
SIMOES, J.A., BAHAMONDES, L.G., TAKIZAWA, E., TAKIZAWA, D., the effect of fluconazole on zidovudine
CAMARGO, R.P.S., ALVES, V.M.N , HIRAOKA, H., SAITO, S. & GOTO, F. glucuronidation: 427
ZANEVELD, L.J.D., WALLER, D.P., Disposition and pharmacodynamics of UNNEBRINK, K. see HESSE, C.
SCHWARTZ, J., CALLAHAN, M.M. & propofol during isovolaemic haemorrhage UNO, T. see MIURA, M.
MAUCK, C.K. A pilot clinical trial followed by crystalloid resuscitation in UNO, T. see SHIMIZU, M.
comparing an acid-buffering formulation humans: 256 UNO, T. see YASUI-FURUKORI, N.
(ACIDFORM gel) with metronidazole TALON, D. see MULLER, A. UNO, T., OHKUBO, T., MOTOMURA, S.
gel for the treatment of symptomatic TAL-SINGER, R. see SINGH, D. & SUGAWARA, K. Effect of grapefruit
bacterial vaginosis: 211 TANAKA, T. see MURAKAMIL, Y. juice on the disposition of manidipine
SIMPSON, J.A., HUGHES, D.., TASHIRO, M., MOCHIZUKI, H., enantiomers in healthy subjects: 533
MANYANDO, C., BOJANG, K., SAKURADA, Y., ISHII, K., ODA, K., UNO, T., SHIMIZU, M., YASUI-
AARONS, L., WINSTANLEY, P., KIMURA, Y., SASAKI, T., ISHIWATA, FURUKORI, N., SUGAWARA, K. &
EDWARDS, G., WATKINS, W.A. & K. & YANAI, K. Brain histamine H TATEISHI, T. Different effects of
WARD, S. Population pharmacokinetic receptor occupancy of orally fluvoxamine on rabeprazole
and pharmacodynamic modelling of the administered antihistamines measured by pharmacokinetics in relation to CYP2C19
antimalarial chemotherapy positron emission tomography with ''C- genotype status: 309
chlorproguanil/dapsone: 289 doxepin in a placebo-controlled crossover
SINGH, D., TAL-SINGER, R., study design in healthy subjects: a VAN DER CAMMEN, T.J.M. see ZIERE,
FAIFERMAN, I., LASENBY, S., comparison of olopatadine and ketotifen: G.
HENDERSON, A., WESSELS, D., 16 VAN DER ENDE, M. see BURGER, D.
GOOSEN, A., DALLOW, N., VESSEY, TATEISHI, T. see MIURA, M. VAN DER HEIDEN, I. see BURGER, D
R. & GOLDMAN, M. Plethysmography TATEISHI, T. see SHIMIZU, M. VAN DER KLAAUW, A.A. see PEREIRA,
and impulse oscillometry assessment of TATEISHI, T. see UNO, T. A.M.
tiotropium and ipratropium bromide; a TATEISHI, T. see YASUI-FURUKORI, VAN DOORN, J. see PEREIRA, A.M.
randomized, double-blind, placebo- N. VAN GIERSBERGEN, P.L.M. see
controlled, cross-over study in healthy TATZBER, F. see RESCH, U. DINGEMANSE, J.
subjects: 398 TERHAAG, B. see BERNSDORF, A. VAN SCHAIK, R. see BURGER, D.
SINGH, S. see SIDHU, J. THEIS, J.G.W. see SIDHU, J. VAN THIEL, S.W. see PEREIRA, A.M.
SINZINGER, H. see RESCH, U. THEUNISSEN, E.L., VERMEEREN, A. & VAUTIER, S. see WYPLOSZ, B.
SKELLY, M.M. see HAWKEY, C.J. RAMAEKERS, J.G. Repeated-dose VERDIGLIONE, P. see TODROS, T.
SKINNER, J.R. see HARRISON- effects of mequitazine, cetirizine and VERGANI, P. see TODROS, T.
WOOLRYCH, M. dexchlorpheniramine on driving and VERMEEREN, A. see THEUNISSEN, E.L.
SMIT, J.W.A. see PEREIRA, A.M. psychomotor performance: 79 VERSCHUREN, W.M.M. see MANTEL-
SOMOGYI, A.A. see DAVIES, B.J. THOMSON, A.H. see STAATZ, C.E. TEEUWISSE, A.K.
SOMOGYI, A.A. see MORRISH, G.A. THUILLEZ, C. see JOANNIDES, R. VESSEY, R. see SINGH, D.
SOMOGYI, A.A. see POLASEK, T.M. TIRONA, R.G. & BAILEY, D.G. Herbal VIGO, J.-M. see CASTEL, J.-M
SOOS, G. see MATUZ, M. product—drug interactions mediated by VILLA, R. see BRUNNER, M.
SPRENGER, H. see BURGER, D. induction: 677 VOELKER, J.R. see YEO, K.P.
STAATZ, C.E.. BYRNE, C. & THOMSON, TITCHEN, T., CRANSWICK, N. & VOLLEBREGT, J.A., METZ, J.C.M., DE
\.H. Population pharmacokinetic BEGGS, S. Authors’ response: Adverse HAAN, M., RICHIR, M.C.,
modelling of gentamicin and drug reactions to NSAIDs: 240 HUGTENBURG, J.G. & DE VRIES,
vancomycin in patients with unstable TODROS, T., VERDIGLIONE, P., OGGE, T.P.G.M. Curriculum development in
renal function following cardiothoracic G., PALADINI, D., VERGANI, P. & pharmacotherapy: testing the ability of
surgery: 164 CARDAROPOLI, S. Low incidence of preclinical medical students to learn
STACK, W.A. see HAWKEY, C.J. hypertensive disorders of pregnancy in therapeutic problem solving in a
STAMS, K.R. see GRIMM, S.W. women treated with spiramycin for randomized controlled trial: 345
STEPHENSON, T. The medicines for toxoplasma infection: 336
children agenda in the UK: 716 TOMLINSON, B. & CHOW, M:S:S. WAITMAN, D.-A. see KAHAN, N.R.
STRICKER, B.H.CH. see MANTEL- Stereoselective interaction of manidipine WALLER, D.P. see SIMOES, J.A.
TEEUWISSE, A.K. and grapefruit juice: a new twist on an WALLER, P. see BARROW, P.
STRICKER, B.H.CH. see ZIERE, G. old tale: 529 WALLER, P.C., EVANS, S.J.W. & BEARD,
SUGAWARA, K. see SHIMIZU, M. TONNING, J.M. see LEVINE, J.G. K. Drug safety and the media: 123
Br J Clin Pharmacol | 61:6 | 795
| Author Index
WALSH, L. Incidental events in spontaneous LOUET, A. & CAPRON, L. Tolerance of VOELKER, J.R., BURKEY, J.L. &
reports a proposal for filtering ‘noise’: diclofenac after hypersensitivity to WISE, S.D. Pharmacokinetics of
118 celecoxib and to nabumetone: 474 ruboxistaurin are significantly altered by
WANG, B. see DONNELLY, R. rifampicin-mediated CYP3A4 induction:
WARD, S. see SIMPSON, J.A. YAMADA, H., SESOKO, S., DAIMON, T. 200
WARREN, J. see RITTER, J & NAKASHIMA, M. Application of a YEO, K.R. see REHILL, N.
WATKINS, W.A. see SIMPSON, J.A. newly designed electronic monitoring YEO, W.W. see REHILL, N.
WEGNER, D. see BERNSDORF, A. device for press through packaging
WESSELS, D. see SINGH, D. sheets in a clinical trial: 238 ZANEVELD, L.J.D. see SIMOES, J.A.
WILLIAMS, J.A. see UCHAIPICHAT, V YANAIT, K. see TASHIRO, M. ZHANG, M. see GARDINER, S.J.
WINNER, L.K. see UCHAIPICHAT, V. YASUI-FURUKORI, N. see MIURA, M. ZIEGLER, S. see BRUNNER, M.
WINSTANLEY, P. see SIMPSON, J.A YASUI-FURUKORI, N. see UNO, T. ZIERE, G., DIELEMAN, J.P., HOFMAN,
WINTER, H.R. see GRIMM, S.W YASUI-FURUKORI, N., UNO, T., A., POLS, H.A.P., VAN DER
WISE, L. see BARROW, P. KANEKO, S. & TATEISHI, T. Author’s CAMMEN, T.J.M. & STRICKER,
WISE, S.D. see YEO, K.P. reply: Hydroxylation of lansoprazole in B.H.CH. Polypharmacy and falls in the
WRISHKO, R.E. see FORGUE, S.T. poor metabolizers of CYP2C19: 361 middle age and elderly population: 218
WYPLOSZ, B., VAUTIER, S., LILLO-LE YEO, K.P., LOWE, S.L., LIM, M.T., ZONDAG, E. see HESSE, C.
796 | 61:6 | Br J Clin Pharmacol
British Journal of Clinical Pharmacology
SUBJECT INDEX
This index was compiled from the keywords
§-adrenoceptor blockers, 513 Chilean population, 778 drug therapy, 716, 761
[l-opiate-agonist, 27 China, 666, 702 drug therapy/adverse effects, 371
6B-hydroxycortisol, 200 chlorcycloguanil, 289 drug utilization, 96
ACE inhibitors, 502 chlorproguanil, 289, 690 drug utilization analysis, 341
ACIDFORM, 211 chronic medication, 352
activated charcoal, 177 ciclosporin A, 671 efavirenz, 148, 601
adult growth hormone deficiency, 451 ciprofibrate, 694 elderly, 218, 229
adverse cardiovascular events, 464 ciprofloxacin, 138 elderly patients, 494, 502, 513, 521
adverse drug reaction, 233 citalopram, 177 electrolytes, 87
adverse effects, 738 clearance, 545 emergency hormonal contraception, 605
adverse events, 224 clinical pharmacology, 389, 787 enantiomer, 315, 533
ad‘erse oesophageal effects, 470 clinical pharmacology and therapeutics, 345 endothelin, 405
age, 605 codispensing, 470 endothelium, 767
aldosterone, 738 cognitive skills, 345 enzyme induction, 200, 246, 246
alendronate, 470 combined oral contraceptive, 191 epidemiology, 229, 730
allometric scaling, 545 communication, 702, 787 epilepsy, 246
amikacin, 39 community consumption, 96 erectile dysfunction, 280
analgesics, 389 comparison, 720 ethnic origin, 405
angiotensin receptor blockers, 502 compliance, 352 ethnicity, 148
antibacterials, 96 computer decision support, 371 exercise, 127
anticoagulants, 229 congenital long QT syndrome (LQTS), 464 exponents, 545
antiepileptic drugs, 246 congestive cardiac failure, 502, 513 extreme preterm infants, 39
antihistamine, 79 coronary artery disease, 720
antimicrobial use, 585 coumarins, 746 falls, 218
antioxidant treatment, 5 crystalloid resuscitation, 256 fexofenadine, 538
antioxidants, 774 cyclosporin, 706 first-generation antihistamine, 16
arousal, 752 CYP2B6 polymorphism, 148 fluconazole, 427
artemisinin, 666 CYP2C19, 309, 315 fluoxetine, 155
arteries, 767 CYP2C8, 70, 746 fluvoxamine, 309
artesunate, 690 CYP2C8 polymorphism, 49 food, 682
aspirin, 730 CYP2D6, 321 food effect, 31
autoantibodies, 262 CYP2D6 polymorphism, 558
CYP3A4, 200, 533 gastrointestinal transit, 31
bacterial vaginosis, 211 Cypher, 720 Ge Hong, 666
bioequivalence, 275 cytochrome P450, 321, 379, 570 gender, 148, 682
bisphosphonates, 521 cytochrome P450 enzymes, 677 genetic polymorphisms
bladder, 456 genetic variants, 778
bone fractures, 521 dapsone, 289, 690 gentamicin, 164
breast milk, 155 defined daily dose, 585 geriatric medicine, 218
British National Formulary for Children, 716 depression, 155 geriatrics, 558
budesonide, 31 determinants of antibiotic use, 96 glucoronidation, 326, 427
detrusor overactivity, 456 grapefruit juice, 49, 682
calcitriol, 470 development, 355 gyu ideline adherence, 592
carbamazepine, 58 Diabetes mellitus, 702
cardiac, 727 diazepam, 752 haemodynamic, 127
cardiac failure, 727 diltiazem, 538 HapMap, 783
cardiothoracic surgery, 164 diphenhydramine, 752 HDL-cholesterol, 601
cardiovascular risk, 494, 502, 601 DNA polymorphisms, 778 healthy subject, 398
case-control, 730 dosage, 671 Herbal formulations, 677
case-control studies, 229 driving, 79 HES data, 233
catecholamines, 127 drug discovery, 666 histamine H,-receptor (HR), 16
cefuroxime, 341 drug interaction, 58, 70, 538, 671, 741 histamine H,-receptor occupancy, 16
celecoxib, 101 drug interactions, 246, 427, 677 HIV, 379
cetirizine, 79 drug resistance, 690 HIV-infection, 5
children, 545, 706 drug safety, 123, 233 HIV infection, 148, 601
© 2006 Blackwell Publishing Ltd BJr Cl in Pharmacol | 61:6 | 797-799 | 797
Subject Index
hospital, 585 monitoring, 371 postpartum, 155
hospital admission, 23 morphine, 326 pravastatin, 706
human, 101 motion sickness, 27 pregnancy, 155
human pain models, 389 MRP2, 440 pregnancy-induced hypertension, 336
hydroxymethylglutaryl-CoA reductase myocardial infarction, 513, 730 prevention and control, 371
inhibitors, 592 primaquine, 682
hyperalgesia, 389 N-acetylcysteine, 5 primary care, 87
hypercholesterolaemia, 592 nausea, 27 primary prevention, 494
hyperlipidaemia, 694 needle-free, 451 prior authorization, 341
hypokalaemia, 87 neural mechanisms, 761 propofol, 256
hyponatraemia, 87 neurokinin-| receptor antagonist, 414 propranolol, 127
nitric oxide, 767 protein kinase C B, 200
Ix, currents, 464 noncompetitive, 326 psychomotor performance, 79
impulse oscillometry, 398 NONMEM, 558 pulmonary disease, 5
in vitro-in vivo correlation, 427 non-nucleoside reverse transcriptase pupil, 752
incidence, 470 inhibitor, 148
indicators, 585 Non-selective non-steroidal anti- qinghaosu, 666
induction, 677 inflammatory drugs, 738 QT interval, 177
ineffectiveness nonselective COX inhibitors, 39 QT prolongation, 464
inhibition, 326 non-steroidal anti-inflammatory drugs, quetiapine, 58
interaction, 191 730
Internet, 787 nonsteroidal anti-inflammatory drugs, 389 rabeprazole, 309, 315
ion channels, 301 norfluoxetine, 155 radiocontrast-induced nephropathy, 5
isoniazid, 570 randomized controlled trials, 494, 502, 51% ~a s
isoquine, 690 OATPIB1, 440, 706 521
isovolaemic haemorrhage, 256 olanzapine, 420 rare diseases, 35
itraconazole, 538 olopatadine, 16 recombinant human growth hormone, 451
ivabradine, 127 orphan drugs, 355 regional differences, 96
Osteoporosis, 521 repaglinide, 49
Japanese, 405 oxidative stress, 262, 74 repeated-dose, 79
oxidatively modified low-density lipoprotein, research, 702, 787
KCNQI, 464 262 retinal blood flow, 138
ketoconazole, 58 review, 246
ketotifen, 16 paediatrics, 716 rifampicin, 138, 200, 70
paraoxonase, 694 risk drugs, 218
lactation, 101 paroxetine, 224, 558 root mean square error, 545
lamotrigine, 191, 420 patients’ perspective, rosuvastatin, 262
Lapdap 690 pentoxifylline, 138 ruboxistaurin, 200
lasotoxifene, 7A}/4 1 perhexiline, 321
light reflex, 752 personalized prescribing, 783 saquinavir, 379
long QT syndrome, 301 P-glycoprotein, 379, 440, 538 secondary prevention, 494
loperamide pharmacodynamics, 177, 191, 256, 289, 405, second-generation antihistamine, 16
lung function, 398 741 selective serotonin reuptake inhibitors,
pharmaco-epidemiology, 218 VIA +
Malaria, 666, 682, 690 pharmacoepidemiology, 341 sentinel effect, 341
managed care, 341 pharmacogenetics, 746, 778 serious motor vehicle crash,
manidipine, 533 pharmacogenomics, 783 sex, 379
MAO inhibitors, 570 pharmacokinetic model, 671 sibutramine, 464
‘
mass media, | 4 pharmacokinetics, 39, 58, 70, 101, 138, 148, side-effects, 352
mechanism-based inactivation, 570 191, 275, 280, 379, ¢ 5. 414, 420, 538, simvastatin, 440
media, 224 558. 682. 741 skin conductance, 7 52
Medicines for Children, 716 pharmaco-scintigraphy, 31 SLCOIB1, 706
medicines regulation, 37] pharmacovigilance, 123, Sleep disorders, 761
mequitazine, 79 pharmacy, 605 sleep-promoting system, 761
meta-analysis, 720 phosphodiesterase, 280 SLV317, 414
metabolic ratio, 321 pioglitazone, 70 smoking, 730, 767
metabolic syndrome, 694 placebo-controlled crossover study design, spiramycin, 336
metabolism, 70 16 St John’s wort, 671, 677
metabolite effects, 138 plasma concentrations, 601 Statins, 494
methadone, 326 Plasmodium falciparum, 289 Stem cells,
metronidazole, 211 polymorphism, 321 stereoselective drug disposition, 155
microbicide, 211 polypharmacy, 218 stereoselectivity, 326
milk, 101 population pharmacokinetics, 164, 289 stress hormones, 27
modelling, 177 positron emission tomography (PET), 16 substance P, 414
61:6 Br J Clin Pharmacol
Subject Index |
tadalafil, 280 time trends, 224 vaginal formulation, 211]
talinolol, 440 tolerability, 420 vancomycin, 164
target concentration intervention, 39 toxicology, 177 variability, 39
targeted drug delivery, 31 toxoplasmosis, 336 vascular damage, 774
Taxus, 720 traditional Chinese medicine, 702 vein, 414
TDS”, 275 training, 702, 787 vitamin D, 521
testosterone, 275 tramadol, 456 VKORC1, 746
tezosentan, 405 transdermal delivery, 275
wakefulness-promoting systems, 76]
therapeutic drug monitoring, - treatment, 456
warfarin, 229, 741, 746
therapeutic problem solving, : TSER, 778
world wide web, 787
thiazide diuretics, 87
thromboembolism, 746 UDP-glucuronosyltransferase, 427 Yellow Card, 233
thrombolytic agents, 513 undergraduate medical education, 345
tilt, 127 urinary incontinence, 456 zidovudine, 427
Br J Clin Pharmacol 61:6 799
Contents
Volume 61, Number 1, January 2006
Editors’ view Drug interactions
Effects of cytochrome P4!
Review
In vivo receptor imaging Therapeutics
ed
niorpneniran
Pharmacoepidemiology
Pharmacodynamics " gional variations in con
Ll ainy
Short report
Pharmacokinetics
Letters to the editors
Drug metabolism
Volume 61, Number 2, February 2006
Editors’ view
121 M J
Review ao
123 Dr sft i ae ay sae ene Pharmacokinetics
terpatient variability
Pharmacodynamics
127 mparative etiect
id norfluoxetine during
K.U Riggs >. Misr
C. Fitzgerald & D.W. Rurak